VANCOUVER – Drug developer Cardiome Pharma Corp. (TSX:COM) reported a net loss in the latest quarter as the company’s revenues fell sharply after a major milestone payment it booked last year.
The Vancouver heart drug treatment company said Friday it posted a net loss of US$7.2 million or 12 cents a share for the third quarter ended Sept. 30.
That reverses a net profit of $22.8 million or 37 cents for the same period last year.
Get weekly money news
The company, which reports in U.S. dollars, said the 2010 results were boosted by a $30 million milestone payment from global drug maker Merck for the marketing approval in Europe of vernakalant.
The drug developed by Cardiome is used to treat irregular heart beat.
Total revenue fell to about $0.3 million from $30.2 million last year.
Meanwhile, research and development spending rose to $3.9 million from $3.5 million, while general and administration costs fell to $2.7 million from $3.5 million.
Cardiome develops treatments for disorders of the heart and circulatory system.
In Friday trading, Cardiome shares dropped 22 cents to $2.90, a decline of more than seven per cent.
Comments
Want to discuss? Please read our Commenting Policy first.